Humacyte, Inc. (HUMA): Total Assets
$116.37M
As of 2025-12-31
$138.09M
As of 2026-06-30
-17.1%
3-year compound annual growth
+1.8%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $116.37M | -15.6% | 2026-03-27, Balance as of period end |
| 2024-12-31 | $137.87M | +7.5% | 2026-03-27, Balance as of period end |
| 2023-12-31 | $128.22M | -37.2% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $204.30M | -28.7% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $286.53M | +168.6% | 2023-03-24, Balance as of period end |
| 2020-12-31 | $106.69M | n/a | 2022-03-29, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Humacyte, Inc. (HUMA) | 2025-12-31 | $116.37M | -15.6% |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | $88.53M | +26.3% |
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | $18.58M | -35.5% |
| Dyadic International Inc (DYAI) | 2025-12-31 | $9.95M | +0.2% |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | $11.63M | -13.5% |
| Inhibrx Biosciences, Inc. (INBX) | 2025-12-31 | $146.48M | -19.0% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $98.73M | +103.7% |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $2.27B | +1.0% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $791.59M | +4.9% |
Compare HUMA, ALGS, OTLK, DYAI side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗